High EGFR expression a predictor for improved survival with cetuximab plus chemotherapy
July 5, 2011 in CancerHigh epidermal growth factor receptor (EGFR) expression was a good predictor of which lung cancer patients would survive longer when cetuximab (Erbitux) was added to first-line chemotherapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).
"The new analysis of the Phase III FLEX study has allowed us to identify which non-small cell lung cancer patients are most likely to benefit from treatment with Erbitux in the first-line setting," said principal investigator Dr. Robert Pirker of the Medical University of Vienna in Austria. "By demonstrating that high EGFR expression is the first predictive biomarker for improved overall survival in advanced NSCLC, we have taken a major step towards a more personalized approach in this difficult-to-treat disease."
Based on a new analysis of all FLEX patients (1,121 out of 1,125 FLEX study patients), researchers found that patients with high tumor EGFR expression (200 and above on a scale of 0-300) consistently benefited from the addition of cetuximab to chemotherapy regardless of histology. Within this group, overall survival averaged 12 months, compared with 9.6 months for patients receiving chemotherapy alone.
In patients with low EGFR expression, no difference in overall survival was seen between patients receiving chemotherapy plus cetuximab, compared to those receiving chemotherapy alone.
Provided by International Association for the Study of Lung Cancer
-
Adding cetuximab to chemotherapy reduces advanced lung cancer death risk by 13 percent
Sep 22, 2009 |
not rated yet |
0
-
Study finds that lung cancer patients respond to erlotinib following cetuximab therapy
Aug 02, 2009 |
not rated yet |
0
-
Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors
Oct 12, 2010 |
not rated yet |
0
-
Patient age not a factor in use of second-line therapy for lung cancer
Mar 03, 2010 |
not rated yet |
0
-
Gefitinib improves survival compared with standard chemotherapy in lung cancer patients with genetic mutation
Dec 20, 2009 |
not rated yet |
0
-
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
3 hours ago |
not rated yet |
0
-
Limits to growth: Scientists identify key metastasis-enabling enzyme
May 22, 2012 |
5 / 5 (3) |
0
-
Seeing is as seeing does: Spatially-structured retinal input in early development of cortical maps
Apr 26, 2012 |
5 / 5 (4) |
1
-
Dreamless nights: Brain activity during nonrapid eye movement sleep
Apr 09, 2012 |
4.4 / 5 (12) |
0
-
Take your time: Neurobiology sheds light on the superiority of spaced vs. massed learning
Mar 28, 2012 |
4.5 / 5 (21) |
3
-
A question about drug tolerance
May 23, 2012
-
Poor nutrition leading to overeating?
May 23, 2012
-
Math and dyslexia?
May 21, 2012
-
portable metabolism meter?
May 21, 2012
-
Rare medical conditions on 20/20 tonight
May 18, 2012
-
"Good" Cholesterol in Doubt
May 17, 2012
- More from Physics Forums - Medical Sciences
More news stories
Cancer may require simpler genetic mutations than previously thought
Chromosomal deletions in DNA often involve just one of two gene copies inherited from either parent. But scientists haven't known how a deletion in one gene from one parent, called a "hemizygous" deletion, can contribute ...
Cancer
33 minutes ago |
not rated yet |
0
|
New prostate cancer screening guidelines face a tough sell, study suggests
(Medical Xpress) -- Recent recommendations from the U.S. Preventive Services Task Force (USPSTF) advising elimination of routine prostate-specific antigen (PSA) screening for prostate cancer in healthy men are likely to encounter ...
Cancer
3 hours ago |
not rated yet |
1
Nonsmoking lung cancer survivor encourages others to consider risk
Carol Seibert had an upper respiratory infection she just couldn’t seem to shake. The timing of her illness was awful, as she had just returned from a trip to Florida for her youngest son’s surgery and was preparing ...
Cancer
6 hours ago |
not rated yet |
0
Brentuximab vedotin effective in large-cell lymphoma
(HealthDay) -- More than half of patients with relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) treated with the CD30-directed antibody-drug conjugate brentuximab vedotin achieve a complete ...
Cancer
17 hours ago |
not rated yet |
0
Childhood cancer scars survivors later in life
Scars left behind by childhood cancer treatments are more than skin-deep. The increased risk of disfigurement and persistent hair loss caused by childhood cancer and treatment are associated with emotional distress and reduced ...
Cancer
20 hours ago |
not rated yet |
0
Inherited DNA change explains overactive leukemia gene
A small inherited change in DNA is largely responsible for overactivating a gene linked to poor treatment response in people with acute leukemia.
Implantable pain disk may help those with cancer
An estimated 3.5 million cancer patients around the globe are in severe pain from their disease, but many get no relief.
In Spain, 70 percent of women use contraceptives during their first sexual encounter
Contraceptive use in Spain during the first sexual encounter is similar to other European countries. However, there are some geographical differences between Spanish regions: women in Murcia use contraceptives ...
World Health Assembly endorses new plan to increase global access to vaccines
Ministers of Health from 194 countries at the Sixty-fifth World Health Assembly today endorsed a landmark Global Vaccine Action Plan (GVAP), a roadmap to prevent millions of deaths by 2020 through more equitable access to ...
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
(Medical Xpress) -- Regardless of an organism’s biological complexity, every encephalized animal continuously makes under-informed behavioral choices that can have serious consequences. Despite its ubiquity, ...
First study to suggest that the immune system may protect against Alzheimer's changes in humans
Recent work in mice suggested that the immune system is involved in removing beta-amyloid, the main Alzheimer's-causing substance in the brain. Researchers have now shown for the first time that this may apply in humans.
